Gross profit ranking of listed companies of nucleic acid detection reagents (list in the third quarter of 2022)

According to the data of the financial report tool of the trend stock selection system, as of the third quarter of 2022, Livzon Group ranked first in the gross profit ranking of listed companies of nucleic acid detection reagents, with a gross profit of 2 105 million yuan; Daan gene ranked second with a gross profit of 65.438+88.5 million yuan; Dean Diagnostics ranked third with a gross profit of 65.438+78 billion yuan. 10 also includes Mingde Bio, watson biological, Cape Bio, Sheng Xiang Bio, Runda Medical, Huada Gene and Master Bio.

1, Livzon Group: 2150,000 yuan.

Company location: Guangdong

Industry: pharmaceutical manufacturing

In the third quarter of 2022, the company achieved a total revenue of 3 1.86 billion, a year-on-year increase of1.66%; Gross profit is 210.05 billion, and gross profit rate is 66.08%.

Second place, Daan gene: 65.438+88.5 million yuan.

Company location: Guangdong

Industry: Medical Devices

The quarterly report of Daan Gene in the third quarter of 2022 shows that the company achieved a total operating income of 2.66 billion yuan, a year-on-year increase of 23.46%; The gross profit is 65.438+88.5 million yuan, and the gross profit rate is 70.89%.

No.3, Dean's diagnosis: 65.438+78 million yuan.

Location of the company: Zhejiang

Industry: medical services

Dean Diagnostics' quarterly report in the third quarter of 2022 shows that the company achieved a total operating income of 4.876 billion yuan, a year-on-year increase of 37.48%; Gross profit is 65.438+0.78 billion yuan, and gross profit rate is 36.5%.

No.4, Mingde Bio: 65.438+53.6 million yuan

Company location: Hubei

Industry: Medical Devices

The quarterly report of the company in the third quarter of 2022 shows that the total revenue in the third quarter of 2022 was 2210.70 billion, a year-on-year increase of10.78.10.4%; Gross profit is 65,438+0.536 million, and gross profit rate is 69.29%.

No.5, watson biological:1.21.70 million yuan.

Company location: Yunnan

Industry: biological products

In the third quarter of 2022, the company achieved a total revenue of 654.38+358 million, a year-on-year increase of 74.24%; Gross profit1.21.70 million, with a gross profit margin of 89.58%.

Sixth place, Cape Biology: 956 million yuan.

Company location: Guangdong

Industry: Medical Devices

In the third quarter of 2022, Cape Bio-Company achieved a total revenue of141600 million, a year-on-year increase of104.33%; The gross profit is 956 million, and the gross profit rate is 67.49%.

Seventh place, Sheng Xiang Biology: 802 million yuan.

Company location: Hunan

Industry: Medical Devices

The quarterly report of the company in the third quarter of 2022 shows that the total revenue in the third quarter of 2022 was10.378 billion, a year-on-year increase of10.654, 38+0.25%; The gross profit is 802 million, and the gross profit margin is 58.2 1%.

Eighth place, Runda Medical: 798 million yuan.

Location of the company: Shanghai

Industry: medical services

In the third quarter of 2022, Runda Medical achieved a total revenue of 2.873 billion, a year-on-year increase of19.88%; The gross profit is 798 million, and the gross profit rate is 27.76%.

No.9, Huada Gene: 767 million yuan

Company location: Guangdong

Industry: Medical Devices

In the third quarter of 2022, BGC achieved a total revenue of135.3 billion, a year-on-year increase of-10.17%; The gross profit is 767 million, and the gross profit rate is 56.73%.

10, Shi Shuo biological: 632 million yuan.

Company location: Jiangsu

Industry: Medical Devices

In the third quarter of 2022, the company achieved a total revenue of 65.438+0.28 billion, a year-on-year increase of-654.38+0.32%; Gross profit is 632 million, and gross profit margin is 6 1.52%.

All the information in Southern Fortune Network does not constitute investment advice, and the stock market is risky, so investment needs to be cautious.